Shirley M. Clift

Health Technology

Consumer Services

Profile

Shirley M.
Clift worked as Vice President-Regulatory Affairs at Cell Genesys, Inc. from 1997 to 2009 and at Sangamo Therapeutics, Inc. from 2010 to 2019.
She obtained an undergraduate degree from the University of California, Berkeley.

Former positions of Shirley M. Clift

Companies	Position	End
SANGAMO THERAPEUTICS, INC.	General Counsel	2018-12-31
Cell Genesys, Inc. Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.	General Counsel	2008-12-31

See the detail of Shirley M. Clift's experience

Training of Shirley M. Clift

University of California, Berkeley

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Shirley M. Clift's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SANGAMO THERAPEUTICS, INC.	Health Technology

Private companies	1
Cell Genesys, Inc. Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.	Health Technology